# Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine

> **NCT00347958** · PHASE4 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 545 (actual)

## Conditions studied

- Tetanus
- Diphtheria
- Pertussis

## Interventions

- **BIOLOGICAL:** Tetanus-diphtheria-acellular pertussis (Tdap) vaccine

## Key facts

- **NCT ID:** NCT00347958
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-02
- **Final completion:** 2008-10
- **Target enrollment:** 545 (ACTUAL)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00347958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00347958, "Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00347958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*